RAS inhibitors increase ACE2 levels to conserve organs from Ang II overload, which keeps the heart across different stresses and may assist patients with COVID-19 with cardiovascular diseases (CVDs) (Ferrario et al., 2020). This evidence concerns the gene ACE2 and COVID-19.